ランキング価格はじめての方へ
  1. 米国企業
  2. RECURSION PHARMACEUTICALS, INC.

RECURSION PHARMACEUTICALS, INC.RXRX

時価総額
$16.3億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2021年
12月31日		2022年
12月31日		2023年
12月31日
Net loss-186-239-328
Depreciation and amortization81224
Stock-based compensation152854
Asset impairment-31
Lease expense-88
Loss on debt extinguishment-1--
Other, net-4-1-3
Other receivables and assets508
Unearned revenue-10110-41
Accounts payable22-1
Accrued development expense113
Accrued expenses and other current liabilities13-17
Operating lease liabilities--7-10
Net cash used in operating activities-159-84-288
Net loss-186-239-328
Depreciation and amortization81224
Stock-based compensation152854
Asset impairment-31
Lease expense-88
Loss on debt extinguishment-1--
Other, net-4-1-3
Other receivables and assets508
Unearned revenue-10110-41
Accounts payable22-1
Accrued development expense113
Accrued expenses and other current liabilities13-17
Operating lease liabilities--7-10
Net cash used in operating activities-159-84-288
Purchases of property and equipment403712
Net cash and restricted cash acquired in the acquisition of a business---2
Net cash and restricted cash acquired in the acquisition of a business---2
Purchases of property and equipment403712
Purchase of an intangible asset-01
Purchases of investments301--
Sales and maturities of investments692310
Net cash provided by (used in) investing activities-272193-10
Net cash provided by (used in) investing activities-272193-10
Proceeds from Issuance of Common Stock-144128
Proceeds from Issuance Initial Public Offering463--
Proceeds from equity incentive plans and warrants81113
Repayment of long-term debt1301
Proceeds from equity incentive plans and warrants81113
Net cash provided by financing activities459154140
Repayment of long-term debt1301
Net cash provided by financing activities459154140
Effect of exchange rate changes on cash, cash equivalents and restricted cash--00
Net change in cash, cash equivalents and restricted cash28264-158
Conversion of Stock, Amount Converted448--
Stock Issued--22
Right-of-use asset additions and modifications-45
Accrued property and equipment812
Right-of-use asset additions and modifications-45
Conversion of Stock, Amount Converted448--
Stock Issuance Costs, Noncash1--
Cash paid for interest100
Cash paid for operating leases-710
Cash paid for operating leases-710
Cash paid for interest100
Purchases of property and equipment403712
Net cash and restricted cash acquired in the acquisition of a business---2
Net cash and restricted cash acquired in the acquisition of a business---2
Purchases of property and equipment403712
Purchase of an intangible asset-01
Purchases of investments301--
Sales and maturities of investments692310
Net cash provided by (used in) investing activities-272193-10
Net cash provided by (used in) investing activities-272193-10
Proceeds from Issuance of Common Stock-144128
Proceeds from Issuance Initial Public Offering463--
Proceeds from equity incentive plans and warrants81113
Repayment of long-term debt1301
Proceeds from equity incentive plans and warrants81113
Net cash provided by financing activities459154140
Repayment of long-term debt1301
Net cash provided by financing activities459154140
Effect of exchange rate changes on cash, cash equivalents and restricted cash--00
Net change in cash, cash equivalents and restricted cash28264-158
Conversion of Stock, Amount Converted448--
Stock Issued--22
Right-of-use asset additions and modifications-45
Accrued property and equipment812
Right-of-use asset additions and modifications-45
Conversion of Stock, Amount Converted448--
Stock Issuance Costs, Noncash1--
Cash paid for interest100
Cash paid for operating leases-710
Cash paid for operating leases-710
Cash paid for interest100